Zydus Cadila Signs Pact With Gilead To Make Remdesivir

Drugmaker Zydus Cadila mentioned on Friday it signed a non-exclusive settlement with Gilead Sciences Inc to fabricate and market antiviral drug remdesivir, the primary remedy to indicate enchancment in COVID-19 trials.